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The mononuclear phagocyte-system is  involved in  a  variety of pathological and 
physiological events (1). It is recognized as the major component in the mediation of 
nonspecific resistance against infectious agents and neoplastic diseases (2, 3). A variety 
of agents like endotoxin (4), bacille Calmette-Gu~rin (BCG) 1 (5), Co~ynebacteriumparvum 
(6), and levamisole (7, 8) reportedly enhance the nonspecific resistance of the host to 
infections and tumors. These increases in resistance can reflect a direct stimulation of 
macrophages and/or a modulation of macrophage function by lytnphokines, produced 
by lymphocytes after sensitization with specific antigen (9,  10). 
Recently Fauve and Hevin (11) demonstrated an increase in nonspecific resistance 
of mice after treatment with the bacterial phospholipid extracts from various bacteria, 
which prompted us to initiate further studies of the active principles in bacterial cell 
wall  extracts, which  can  produce nonspecific resistance.  We therefore extracted an 
apolar  lipid  fraction  from  Escherichia  coli  and  studied  its  protective effect against 
infections with supralethal doses of gram-negative and gram-positive bacteria in mice. 
The active component of this apolar lipid extract was purified and identified as the 
benzoquinone ubiquinone-8. 
This paper describes the effects of ubiquinone-8  (QS)  in comparison to other Q- 
analogues (Q4, Q6, and Q10) on host resistance to a variety of pathogens in mice and 
the possible sites of action of QS. A method for the preparative purification of Q8 is 
also described. 
Materials and Methods 
Animals.  Female NMRI  mice weighing =20 g  were obtained from a  commercial breeder, 
and raised in pathogen-free conditions at a  temperature of 20-22°C in the Sandoz Forschungs- 
institut  (SFI) animal care division.  The assay of plaque-forming cells (PFC)  was done with 
spleens  of BnDzF1 and  C3H  mice.  Groups  of  10  or  more  mice  were  used  in  individual 
experiments. 
Bacterial Stratus.  E.  colt' 01,  Salmonella typhimurium, E~ysipelothrix insidiosa, and  Streptococcus 
pyogenes were all obtained from the SFI collection. The doses of infections used were 5-10 times 
higher than doses of bacteria which can cause death of all control mice. The cultures of bacteria 
were stored in liquid nitrogen and diluted in isotonic saline just before infection. 
* Present address: Department f'tir  Junere Medizin, Universit/itsspital ZiJrich, CH-809I  Z/firich R~imi- 
strasse 100, Switzerland. 
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Fxe.  1.  Chromatograms of ubiquinone extract from E. coli separated by silica gel and HPLC. A, 
Pattern of dried ubiquinone extract on silica gel. Arrows indicate ubiquinone containing fractions 
which were taken for further purification. B, HPLC of purified ubiquinone peak. a, collected Q8 
fraction, b, lower quinones. For condition see Materials and Methods. 
Bacterial Challenge.  Appropriate dilutions of the bacteria were injected into the tail veins of 
experimental mice, the controls receiving an equivalent volume (0.3  ml/mouse) of isotonic 
saline. All mice receiving injections of supralethal doses of E.  coli  0l,  S.  typhimurium,  and S. 
pyogenes died within 18-24 h after infection, whereas those that were challenged with E. insidiosa 
died by 3-4 days. The animals that survived the infection, as in the case of Q8 treated animals, 
were kept under observation up to 3 wk. For infectious doses see Table I. 
Bacterial  Clearance  from Blood and Tissues.  For estimation of bacteria in spleen and liver groups 
of 30 mice were injected intravenously with 2  X  l0  s E.  coli 01. At various time intervals the 
bacterial counts of spleen and liver were performed under sterile conditions according to Pierce 
et al.  (12). For the homogenates of the organs, 1 ml saline/100 mg material was used. 
Blood clearance ofE. coli O1 was estimated by injecting groups of 10 mice intravenously  with 
2 ×  108 viable bacteria per animal. At various intervals, the animals were bled from the venous 
plexus of the eye and bacteria were counted after dilution with saline on blood agar plates. 
Isolation of Q8.  Solvents used for the chromatographic separations were degassed  before use; 
di-isopropyl ether was distilled to eliminate the stabilizers and anti-oxidants. Dry bacteria of E. 
coli B M  1135 (Merck A. G. Darmstadt, W. Germany) were extracted with hexane/CHCl3 as 
described by Friss  et  al.  (13). An average yield of 9.0  g extract/kg dry weight bacteria was 
obtained. This extract was dissolved in 100 ml hexane and subjected to a first chromatographic 
separation on a Merck column, type C, filled with silica gel 43-60 #m. The apolar lipids were 
eluted using the following elution scheme: hexane/diethyl ether 99:1, 98:2, and 97:3 with 1.5 
1 of each solvent mixture. Monitoring was done with a Schoeffel SF 770 UV detector tuned at 
404 nm. The constant flow rate of 18 ml/min was achieved by using an Ahex pump (Rainin 
Instrument Corp.,  Brighton,  Mass.).  The  ubiquinones were  eluted with  the  97:3  mixture, 
evaporated to dryness (average 0.5 g of bright yellow dry material), and dissolved in the mobile 
phase used in a  high pressure liquid chromatographic (HPLC) separation (Fig.  1  A).  HPLC 
conditions: stainless steel column 500  ×  8.4 mm i.d., slurry packed with LiChrosorb SI 100, 5 
pm, (Rainin Instrument Corp.), mobile phase hexane/di-isopropyl ether 95:5 vol/vol, flow rate 
12  ml/min, pressure  27  pound per square inch. Fractionation was done by monitoring the 
effluents with a UV detector at 404 nm. The first eluting peak was collected and consisted of 
Q8  with  a  purity >95%  as  checked  by  analytical HPLC,  (Fig.  1 B),  'H  nuclear magnetic 
resonance, and mass spectrometry (14). An average yield of ~ 100 mg Q8 (Fig. 2) was obtained. 
The second peak contained the lower ubiquinones. The more polar lipids remaining on the 
Merck  column were  eluted  from  time  to  time with  1.5  liters  each  of CHC13 followed  by 
methanol. 1230  HOST  RESISTANCE  AND UBIQUINONE 8 
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F,a.  2.  Q8. 
Physical  Properties of Q8.  High  resolution  mass  spectroscopy analysis of Q8  revealed  a 
molecular ion of 726.562  ±  0.006 atomic mass unit  (amu)  (726.559  theoretical for C4~H7,O4) 
and a ubiquinone characteristic fragment ion of 235.095  ±  0.002 amu (235.097  theoretical for 
CxsH1504). In addition all the characteristic smaller fragments reported by Morimoto et al. (14) 
for ubiquinone were also observed. 
Proton magnetic resonance of Q8 HPLC peak (Fig. 1 B) gave the following expected signals: 
olefinic protons 5.12  ppm;  two phenyl-O--CHa at 3.88 ppm and 3.94  ppm;  phenyl-CHs at 
2.16  ppm; the =,C--CH2--CHz--~  group at  1.96-2.10 and the ==C--CHa moiety at  1.62 
ppm. 
Other Ubiquinones,  Q6 and Q10 are commercially available (Sigma Chemical Co., St. Louis, 
Mo.) Ubiquinone-4 was a gift from Dr. K. Folkers, Institute for Biomedical Research, Austin, 
Tex. 
Preparation of the Injection Solutions.  The samples were suspended in sterile saline by a short 
sonieation  (5-10 s)  with a  Branson  sonifier (Branson Sonic Power Corp., Danbury, Conn.). 
During this preparation the solution was stored on ice and protected from light. The particle 
size of the solution was 2-4 #m. 
Lipopolysaccharides.  Lipopolysaccharides (LPS)  from E.  coli 04  (0111/180)  were obtained 
from the Max-Planck-Institut ffir Immunobiologie, Freiburg, W. Germany and were extracted 
by the hot phenol-water method (15). Lipid A antigen was purified following the procedure of 
Galanos et al. (16). 
Macrophage Preparation and EO)throphagocytosis.  Macrophages were harvested from the perito- 
neal cavities of mice, according to the method of Wellek et al. (17). The cells were extensively 
washed in medium TC 199 (Grand Island Biological Co., Grand Island, N. Y.) and adjusted at 
a concentration of 2  ×  106 viable cells/ml, as determined by Trypan blue exclusion. Phago- 
eytosis was performed in Leighton tubes (Bellco Glass, Inc., Vineland, N. J,). The macrophage 
suspension (1.0 ml vol) was put into the tubes and was incubated for 60 rain at 37°C in 5% 
COs. Nonadhering cells were washed offwith medium TC 199. The remaining cells, about 95% 
macrophages,  formed monolayers on  the cover slips. To  each  tube,  antibody-coated sheep 
erythrocytes (SRBC)  (anti-sheep hemolysin 1:6,000)  (Behring Diagnostics, American Hoechst 
7  Corp., Somerville, N. J.) at a concentration of 2.0  ×  10/ml, diluted in 1.5 ml medium TC 199 
were added. Phagocytosis was allowed by incubation for 60 rain at 37°C  and 5% COs. The 
tubes were rinsed with medium TC 199, and noninternalized SRBC we.re iysed by using 0.83% 
ammonium chloride solution. After one more washing step with TC  199, the cover slips were 
removed,  dried, and  stained with  Wright's stain.  Phagocytosis was  calculated by counting 
internalized  SRBC  within  500  macrophages.  Macrophages  were  divided into  four  groups 
containing 0,  1-2, 3-4, and 5 or more erythrocytes/cell. Results were expressed by calculating 
the phagocytic index (P.I.) according to: 
P.I.  -- ~'  pi' xi 
pi 
pi  =  number of maerophages in group i 
xi  =  uptake of SRBC on average. 
Spleen  Plaque-Forming Cell Assay.  Direct  plaque-forming cells  (PFC)  were  assayed  by  a 
modification of the hemolytic plaque technique as reported by Plotz et  al.  (18).  Mice were 
immunized with  10  s  SRBC  on  day 0.  On  day 4  the animals were killed and  a  spleen cell 
suspension  was  prepared  in  Hanks'  balanced salt solution. 400  gl of 0.5%  agarose in  2  ml 
minimal essential medium  (Grand Island Biological Co.)  were dispensed in glass tubes and 
kept at 44°C. 0.01  ml of a  15% suspension of SRBC was added to each tube followed by 100 L.  H.  BLOCK,  A.  GEORGOPOULOS,  P.  MAYER, AND J.  DREWS 
TABLE  I 
Effect of Q8 Treatment of Experimental Infections with Gram-Positive and Gram- 
Negative Organisms in Mice 
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Pathogens  Inoculum/mouse i.v.  Controls*  QS* i.v. 
S. pyogenes 
E. insidiosa 
E. coli Ol 
S. typhimurium 
8 ×  102  0/70  42/70 
3 ×  102  0/70  70/70 
102  0/70  70/70 
1.7  ×  10  n  0/70  49/70 
8  ×  10  2  0/70  70/70 
3 X  l0  s  0/70  70/70 
1X  109  0/70  56/70 
2 ×  l0  s  0/70  70/70 
1 ×  108  15/70  70/70 
1X  10  s  0/70  48/70 
1X  10  s  0/70  70/70 
1X  108  0/70  70/70 
Note: Q8 was injected i.v, (25 rag/ks b.w.) 24 h before bacterial challenge.  Bacterial 
inocula were injected i.v. 
* Survivors  represent mice per total number alive at 24 h after infection with E. coli 
01 and at 4 days after challenge with E. insidiosa. These surviving animals continued 
to live beyond 3 wk after bacterial challenge.  Mice shown represent all the animals 
used in the experiments. 
p,1 of a spleen cell suspension.  The contents of the tube were mixed, then poured over a glass 
slide. The slides had previously been coated with a dilute solution of agarose (0.1% wt/vol) and 
allowed to dry. Subsequently, the slides were incubated on trays in a moist atmosphere at 37°C 
for 1 h. The slides were then flooded with 1:40 dilution of lyophilized guinea pig complement 
(Serotherapeutisches Institut, Vienna,  Austria)  and  incubated  for another 60 min at  37°(2. 
Plaques were counted under a microscope at a magnification of  8 and with indirect illumination. 
The number of plaques was related to 107 spleen cells. 
Results 
Because Q8 was isolated from gram-negative organisms it was assayed for contam- 
ination with endotoxin. Q8 was found to be free of pyrogenicity by testing in rabbits 
at different dosages (25-250 mg/kg). As a positive control bacterial endotoxin purified 
from Proteus vulgaris was  used  at  a  dose of 0.03  #g in  sterile saline.  While  the  Q8- 
treated  rabbits  showed  no  significant  raise  in  body  temperature  (0.1-0.3°C)  the 
endotoxin caused biphasic fever between 0.5 and 1,2°C. In addition, chemical analysis 
for 2-keto-3-deoxyoctonate (KDO-test, according to Warren,  19) and endotoxin assay 
with Limulus polyphemus (20)  were negative in an assay which could detect  1 ng/ml of 
purified LPS. 
When  injected  intravenously  24  h  before  infection,  Q8  at  a  dose  of 25  mg/kg 
provided complete protection against 5-10-fold lethal doses of the inoculum. Table I 
shows  the effect of Q8 on experimental infections with inocula of E.  coli 01  and S. 
typhimurium. The protective effect of Q8  was  also observed when  the  animals were 
infected with S. pyogenes and E. insidiosa (Table I). 
To demonstrate whether LPS extracts from E. coli 04 could reproduce the effect of 
Q8, nonlethal dosages of E. coli 04 lipid A antigen (20-80 #g, containing 2-8 #g lipid 
A) were injected into each mouse 24 h before bacterial challenge. 2¢ h after infection 1232  HOST RESISTANCE AND UBIQUINONE 8 
TABLE II 
Protective Effect of Q8 against Bacterial Challenge with E. coli O  l and E. insidiosa 
as a Function of Time of Administration of Q8 
Treatment*  E. coli 01  E. insidiosa 
Hou~ before inaction  Surviving animals 
Control  S  0/10  0/10 
48  6/10  10/10 
24  10/10  5/10 
8  5/10  4/10 
0  0/10  4/10 
Note:  Q8 was injected i.v. (25  mg/kg b.w.).  Pathogens (2  ×  10  s E,  coli Ol and 8 
×  102 E.  insidiosa)  were injected into mice i.v. at the indicated time intervals after 
injection of QS. The data are derived from one representative experiment of seven. 
Survivors represent mice per total number alive at 24 h after infection with E. coli 
Ol and at 4 days after challenge with E. insidiosa. These surviving animals continued 
to live beyond 3 wk after bacterial challenge. 
Administration of Q8 at varying points of time before bacterial challenge. 
0.3 ml saline/mouse i.v. 
with 2  X  l0  s E. coli O1 the survival was 8% (4/50). 
The  protective  action  of Q8  was  not  a  transient  effect  as  evidenced  by  the 
observation that  the protected animals continued to survive beyond 3 wk.  Simulta- 
neous injections of Q8 along with E. coli Ol did not protect the mice against infections. 
It  was  necessary,  therefore,  to  determine  the  optimal  interval  between  the  prior 
treatment with Q8 and the bacterial infection. Groups of mice were pretreated with 
Q8 and were infected with E. coli O1 at varying time intervals. Table II shows that the 
optimal time for pretreatment with Q8 for maximal protection against E. coli O1 was 
24 h.  Later intervals, e.g. 48 h, were less effective, presumably because of the drug 
clearance from the body. The optimal time for treatment against bacterial infections 
appears to depend on the nature of infection. In animals challenged with E.  insidiosa, 
which represents a  slowly developing chronic infection, Q8 injected as late as 48 h 
before infection was most effective. However, even simultaneous administration of Q8 
imparted partial protection against infection (Table II). 
The protective effect of Q8 injected 24 h  before infection on the survival of mice 
infected with E. coli O1 was dose-dependent. As indicated in Fig. 3, the dose-response 
relationship was not strictly linear. However, when 2  ×  10  s E.  coli O1 bacteria were 
used as the inoculum, the ED~0 was in the range of about 4-10 mg/kg and the ED100 
was --25-30 mg/kg. Because an enhancement of host resistance had previously been 
described by Casey and Bliznakov (21)  for other ubiquinones, the effect of Q8 was 
compared with that of ubiquinones-4, Q6, and Q10 in experimental infections with 
E.  coli  01.  All ubiquinones were injected 24 h  before infection in equal doses of 25 
mg/kg. As demonstrated in Fig. 4, Q8 is 5-10 times more effective, in terms of percent 
survival at a dose of 25 mg/kg body weight (b.w.) in this experimental model. 
The application of BCG and endotoxin results in hypertrophy of the spleen and 
liver of mice by 48 h  (22). We therefore studied the effect of Q8 on both organs. The 
weights of liver and spleen did not change at 48 h  significantly in animals treated 
with a protective dose of Q8 (25 mg/kg b.w.)  (Table III). 
The protective action of Q8 appeared to be directed against a variety of pathogens. 
It  could,  therefore, be suggested  that  Q8  stimulates  the  reticuloendothelial system 
(RES) and consequently enhances the nonspecific resistance of the host. Stimulation L.  H.  BLOCK,  A.  GEORGOPOULOS,  P.  MAYER,  AND J.  DREWS 
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F:c.  4.  Protective effect of four different ubiquinones against experimental infection of mice with 
E. coli 01. Groups of mice (10 animals each) received 25 mg/kg b.w. of ubiquinones i.v. 24 h before 
i.v. challenge with 2  ×  108 E.  coli 01. The data are derived from one representative experiment of 
four. 
of the RES would mean both enhanced clearance (from blood) and sequestration of 
bacterial into the RES as well as destruction of pathogens. 
Experiments were carried out to investigate these possibilities. Groups of mice were 
infected intravenously with 2  ×  l0  s E. coli 01. Fig. 5 shows the bacteria/ml of blood 
at varying times after bacterial challenge. 2 h  after infection, the bacteremia in Q8 
treated mice was nearly  100-fold smaller than in the controls. This could be due to 
enhanced sequestration of bacteria as well as enhanced destruction of bacteria by the 
RES. Fig. 6 demonstrates that in control animals, the bacterial counts in the spleens 
were  increased  severalfold with  time,  indicating  an  uptake  of bacteria  by splenic 
tissue. However, in Q8-treated mice the number of bacteria have, in fact, decreased 1234  HOST  RESISTANCE  AND UBIQUINONE 8 
TABLE III 
Effect of Q8 on the  Weight of Livers and Spleens of Female NMRI Mice 48 h after 
Injection 
Group  Treatment i.v.  Tissue  Weight (mean +  SD) 
mg 
1  Q8  Liver  1,170 +  110 
2  saline  Liver  1,195 -I- 120 
3  Q8  Spleen  107  +  15 
4  saline  Spleen  109 ±  13 
Note: Q8 was injected i.v. at a dose of 25 mg/kg b.w. Controls received 0.3 ml isotonic 
saline per mouse i.v. 
The data are derived from one representative experiment of five, 
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FIe.  5.  Blood clearance ofE. coh" 01. Groups of mice (10 animals each) received 25 mg/kg b.w. Q8 
s  i.v. (.  ~) or served as controls (---). 18 h later all animals were challenged with 2 ×  10  E. coli 
Ol  i.v. and the number of E. colt" Ol was determined in the blood 2,  15, 30, and  120 rain  after 
challenge. The data are derived from one representative experiment of four. 
with time. 24 h  after i.v. challenge with 2  ×  10 s E. coli O1 the QS-treated animals had 
approximately  500  times  less  bacteria  than  the  controls.  Comparable  data  were 
obtained from livers of control and experimental mice (data pertaining to livers not 
shown). Livers and spleens of these animals together accounted for the major amount 
of bacteria injected in control animals at 24 h. 
Phagocytosis by macrophages is a  necessary condition for sequestration of bacteria 
by  the  RES  as  well  as  for  intracellular digestion of bacteria  by  macrophages  (2). 
Peritoneal maerophages offer an excellent tool to test the effects of Q8 in vivo and in 
vitro on the macrophage phagocytosis. Mouse peritoneal macrophages isolated from 
normal animals and those treated with saline, triolein, and Q8 were compared 24 h 
after such  treatment  for their efficacy to internalize SRBC, which were coated with 
antibody  against  SRBC.  Fig.  7  shows  that  triolein and  Q8  significantly increased 
phagocytosis of SRBC, the latter being twice as effective as triolein, and four times as 
effective as the controls.  In  mice pretreated with  Q8  the effect of a  single dose on L.  H.  BLOCK,  A.  GEORGOPOULOS,  P.  MAYER,  AND J.  DREWS 
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Fro.  7.  Erythrophagocytosis of peritoneal mouse macrophages. I, control; II, 0.3 ml saline; III, 30 
mg/kg trioleine in 0.3 ml saline; IV, 30 mg/kg Q8 in 0.3 ml saline. The data are derived from one. 
representative experiment out of six. 
phagocytosis was maximal  at  48 h.  A  second  treatment  with Q8 at  72 h was also 
effective in increasing  phagocytosis by macrophages  (Fig. 8). Daily injections of Q8 
maintained the higher capacity ofmacrophages to internalize SRBC indefinitely (Fig. 
9).  Phagocytosis of SRBC by macrophages  from  normal animals  is increased  when 1236  HOST RESISTANCE AND UBIQUINONE  8 
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Fro. 9.  Phagocytosis  of SRBC by peritoneal macrophages of mice after repeated treatment with 
25 mg/kg Q8 i.v. at 0, 24, 47, 72, 96, 120, and 144 h. These groups of animals were sacrificed at 24- 
h intervals (24 h after each injection of QS), peritoneal macrophages harvested, and the assay of 
erythrophagocytosis performed. The control groups of animals were correspondingly treated with 
saline (- - -) instead of 0_..8 (  ). The data are derived from one representative experiment of five. 
the macrophages are first incubated with Q8 in vitro for 2  h.  Further, this in vitro 
effect of Q8 on phagoeytosis could be demonstrated with a  variety of substances like 
paraffin oil (Red Oil O), blue dextran (mol wt 2  ×  10  e dahons), latex particles, etc. 
(data not shown.) 
The direct plaque-forming cell test of Plotz et al.  (18)  was used to investigate the 
possible action of Q8 on B lymphocytes. Spleen cells were prepared from two different 
strains of mice. PFC was assayed 4 days after immunization  with SRBC as mentioned 
above in Materials and Methods.  Table IV shows  that  in both strains of mice Q8 
enhanced the proportion of PFC to spleen cells significantly, indicating the enhanced 
humoral response in presence of Q8. L.  H.  BLOCK,  A.  GEORGOPOULOS,  P.  MAYER,  AND J.  DREWS 
TABLE  IV 
Effect of Treatment with Q8 on PFC in Vivo of Two Mouse Strains 
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Mice strains  Treatment*  PFC/l0  T spleen cells¢ 
BsD2F1  Q8  6.848  ±  1.595§ 
Control  2.515  ±  919 
CsH  Q8  22.211  ±  5.716~ 
Control  10.005  ±  2.606 
* Mice immunized with l0  s SRBC were treated 24 and 48 h  (twice) before sacrifice 
with 25  mg/kg b.w. of Q8 i.v. PFC were assayed 4 days after immunization with 
SRBC. 
:~ Each PFC is the arithmetic means (±  SD) of 10 mice. 
§ Analysis of variance; significant difference between treated and control group  (P 
<  0.05). The data are derived from 1 representative experiment of 10. 
Discussion 
Stimulation of nonspecific resistance by exogenous agents such  as BCG  (23,  24) 
and levamisole (25) is considered to be of potential value in the treatment of infectious 
diseases and cancer. The observation that the treatment with lipid extracts of  a variety 
of bacteria  (11)  potentiated nonspecific resistance of the host  led us to isolate and 
purify an apolar lipid component from E. coli Ol using HPLC. This isolated compound 
was capable of enhancing host resistance to a variety of pathogens. 
This active compound was identified to be Q8 by nuclear magnetic resonance and 
mass spectrometry. The isoprene side chain length of the ubiquinone appears to be a 
critical determinant for its biological activity. It is interesting to note that other Q- 
analogues (Q10, Q6, and Q4)  were also shown to stimulate host resistance (21, 26). 
Our  data  confirm  these  results  and  further  show  that  the  optimal  chain  length 
corresponds to that of QS. 
Since Q8 was isolated from gram-negative bacteria, it was of crucial importance to 
exclude contamination with bacterial endotoxins which are known to be LPS (27). 
Bacterial endotoxins cause fever and  hepatosplenomegaly, effects which have been 
used  as  bioassays  for endotoxic activities.  Our  preparations  of Q8  were stored  in 
chloroform at  4°C  and  were repeatedly monitored for lack of pyrogenicity at  any 
dose (25-250 mg/kg b.w.). Further, these Q8 preparations did not cause hepatosple- 
nomegaly in  mice or pyrogenic reactions when  tested in  large amounts of rabbits. 
Purification  of Q8  involved  HPLC  in  apolar  solvents.  This  procedure  did  not 
contaminate the samples with endotoxin as evidenced by both a negative KDO test 
(19) and Limulus assay (20). 
The efficacy of Q8  on  host  resistance to infections appears  to be related to  the 
duration of prior treatment and the severity and rapidity of infection. The observation 
that  the  protection  caused  by  Q8  against  both  gram-positive  and  gram-negative 
bacteria could be valuable in the therapeutic use of this compound as an agent  to 
stimulate nonspecific host resistance. 
The experiments on the bacterial clearance from the blood and bacterial counts in 
liver and spleen after infection showed that liver and spleen were the major organs for 
sequestration of bacteria by the RES. Though pretreatment with Q8 enhanced the 
clearance of bacteria from blood compared to controls, the bacterial counts in spleen 
and liver were in fact far less  in Q8 treated animals.  Had Q8 merely increased the 1238  HOST RESISTANCE AND UBIQUINONE 8 
perfusion of liver and spleen, that  would account for only the enhanced clearance 
from blood and not from liver and spleen. This suggested that Q8 indeed potentiated 
the bacteriocidal and/or bacteriostatic mechanisms of the RES. Q8 had no effect on 
bacterial growth in vitro and therefore its possible role in enhanced bacteriolysis could 
be only due to potentiation of the RES function. 
Administration of nonlethal dosages of LPS, although minimally effective, could 
not  reproduce the protective effect of Q8.  In  this regard it is essential to note that 
RES  function of mice 24 h  after receiving nonlethal  doses of LPS is  considerably 
decreased, although it might be increased after 2-3 days of application (22). 
Commercially available LPS is usually extracted by the hot phenol water method 
or  the  trichloroacidic acid  method.  Because  of their  polarity  both  solvents  could 
possibly extract Q8  from bacterial cell walls.  Therefore, commercial LPS prepared 
from Q8-rich strains  (e.g., E. coli)  could very well be contaminated by Q8. The fact 
that both Q8 and LPS are biologically active indicates that former studies performed 
with crude LPS extracts should be re-examined for possible contaminations with Q8 
or its analogues. 
The experiments on erythrophagocytosis using macrophages from Q8-treated and 
control animals  indicated  that  Q8  exerts a  potentiating action on phagocytosis in 
vivo, phagocytosis being a  primary event in bacterial sequestration and subsequent 
destruction by macrophages. 
Q8 caused a marked stimulating effect on phagocytosis of macrophages independent 
of the type of particle internalized and therefore it may be argued that this in vivo 
effect of Q8  on  host  resistance  to  bacterial  infection is  partially  due  to enhanced 
phagocytosis of bacteria. 
Triolein treatment  of animals  is  known  to  enhance  phagocytosis in  phagocytes 
when  tested in  vitro, but  has no significant effect on host  resistance to pathogens. 
Further, Q8 had a disproportionately large effect on host resistance compared to other 
Q-analogues.  These  observations  indicate  that  Q8  has  sites  of action  other  than 
macrophage phagocytosis which contribute to overall host resistance besides phago- 
cytosis. 
The pharmacokinetics of Q8 are apparently different with regard to host resistance 
in vivo, phagocytosis in vivo and in vitro. This could be explained both in terms of 
multiple sites of action of Q8 on the host defense mechanisms as well as in terms of 
the  nature  of partition  and  exchange  of  this  coenzyme  Q-analogue  in  various 
compartments in the body. 
A  possible site of action of Q8 could also be on the humoral  (IgM)  response of B 
lymphocytes. This was tested by the PFC test and the data do support the possibility 
that  Q8  has additional sites of action such as B  lymphocytes. Sugimura et al.  (28) 
have reported that Q7 had a comparable effect in stimulating PFC in mice immunized 
with SRBC. 
The molecular mechanism of action of Q8 could not at present be analyzed either 
in terms of altered membrane function or in terms of its capability to participate in 
redox  reactions.  Further,  the  possible  effects on  B  lymphocytes and  bacteriolysis 
require additional studies by suitable in vitro experimental models. Q8 does, however, 
offer a  useful tool in the potentiation of nonspecific host  resistance against  a  large 
spectrum  of bacteria  and  is  therefore of potential  value  in  the  chemotherapy  of 
infectious diseases and cancer. L.  H.  BLOCK, A. GEORGOPOULOS, P.  MAYER, AND J.  DREWS  1239 
Summary 
A  lipid  fraction from Escherichia  coli  was extracted with  apolar solvents and  was 
found  to  protect  mice  from  a  number  of experimental  bacterial  infections.  The 
benzoquinone, ubiquinone-8, was isolated from this extract by high pressure liquid 
chromatography and  identified  as  such  by nuclear  magnetic  resonance  and  mass 
spectrometry. At a  dose of 25 mg/kg this substance was found to provide complete 
protection against otherwise lethal  infections with gram-negative and gram-positive 
bacteria in mice. Treatment was most effective when given intravenously 24 h before 
infection.  In comparative studies,  ubiquinone-8 had  a  clearly higher activity than 
ubiquinones-4, Q6, and Q10.  A  highly significant  increase in  the clearance rate of 
bacteria from the blood by the spleen and the liver of treated animals, correlated well 
with the protective effect of ubiquinone-8. The compound stimulated  the ability of 
mouse macrophages to incorporate sheep erythrocytes and significantly increased the 
number of antibody-producing cells  in spleens of mice. 
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